Elevated pretreatment serum levels of IP-10 were also associated with increased likelihood of disease relapse and diminished survival in HIV-uninfected patients with diffuse large B-cell lymphoma [45]. This evidence concerns the gene CXCL10 and diffuse large B-cell lymphoma.